David Craig

CEO at Sarcomatrix Therapeutics Corp.

Presenter

At Sarcomatrix, we are pioneering treatments that address the root cause of muscle wasting diseases like sarcopenia, cachexia and muscular dystrophies. Our innovative approach combines gene-modifying oral drugs and protein replacement via IV, offering a potential cure rather than just symptom management.
This positions us uniquely in a market where there are no cures and existing treatments fall short.